NCT07606066ClinicalTrials.gov

A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies

RecruitingTaking participants now, according to the registry record.

Contact this study

In brief

The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient…

Observational2,150 participants sought76 sites7 countries

Registered in 1 registry

ClinicalTrials.govNCT07606066Open this record at ClinicalTrials.govSynced 4 weeks ago

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2026-05-26; recorded start 2026-05-06
Present: Has a defined primary outcomeA primary outcome measure is listed in the record
Present: The primary outcome states a time frameThe primary outcome measure records a time frame
Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
Present: Sponsor has 1019 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database

The record lists 1 condition.
Lead sponsor type recorded as: industry.

These are facts from the public registry record, not a judgement about the study. Discuss any trial with your own doctor before taking part.

What these facts mean, and what to ask · ruleset v1

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built

Randomised allocation0/20
Allocation not stated in the record
Blinding0/20
Masking not stated in the record
Control arm0/15
No comparator arm stated in the record
Primary-outcome specificity10/10
Named primary outcome with a defined time frame
Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
Multi-centre8/8
Multi-centre: 71 sites
Data monitoring committee0/7
No data monitoring committee stated
Prospective registration5/5
Registered before the study start date
Protocol / SAP posted0/5
No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,150 participants (target), run at 76 sites, across 7 countries.

How this score is built

Enrolment33/40
2,150 participants (target)
Site count21/25
71 sites
Country count12/15
7 countries
Planned duration5/10
Planned over about 11 months
Sponsor scale10/10
AstraZeneca has led 991 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built

Investigator standing0/100
No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

Conditions

Type 2 Diabetes

Eligibility

Eligibility
Sex	All
Ages	18 Years – No maximum
Healthy volunteers	No
Sampling method	NON_PROBABILITY_SAMPLE

Study population

Adults with Type 2 Diabetes

Eligibility as written in the registry

Inclusion Criteria: * Participants must be ≥ 18 years of age at the time of signing the ICF. * Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World Health Organization or local diagnostic standards, inadequately managed with: 1. Lifestyle management alone, AND/OR 2. A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF. * Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required. * Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis. Exclusion Criteria: * Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol). * Diagnosed with Type 1 diabetes mellitus. * Known pregnancy at the time of visit or having the intention to become pregnant.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study type	Observational
Phase	Not stated in the registry record
Allocation	Not stated in the registry record
Intervention model	Not stated in the registry record
Primary purpose	Not stated in the registry record
Masking	Not stated in the registry record
Enrolment	2,150 participants sought

Sponsor and collaborators

AstraZeneca Sponsor

Arms and interventions

Participants with Type 2 Diabetes
Participants with Type 2 Diabetes

Interventions

Other Procedure: assessment
The approximate volume of blood required is 2 mL

Outcome measures

Primary outcome
Patient demographics
Summary statistics
Time frame Visit 1 (Single day)
Primary outcome
Medical and surgical history
Summary statistics
Time frame Visit 1 (Single day)
Primary outcome
Concomitant medication
Summary statistics
Time frame Visit 1 (Single day)
Primary outcome
HbA1c levels
Summary statistics
Time frame Visit 1 (Single day)
Secondary outcome
Referral to ongoing or future T2DM study.
Number of participants with high likelihood of meeting eligibility criteria in ongoing or future T2DM studies, for referral to those studies.
Time frame Visit 1 (Single day)

Dates

Dates
Start date	May 6, 2026 (actual)
Primary completion	March 31, 2027 (estimated)
Completion	March 31, 2027 (estimated)
First posted	May 26, 2026 (actual)
Last updated	August 25, 2026
Results posted	Not stated in the registry record
Status last verified	March 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

19 sites are recruiting

Brazil

Brazil
Facility	City	State or region	Status
Research Site	Barretos		Not yet recruiting
Research Site	Brasília		Not yet recruiting
Research Site	Campinas	São Paulo	Not yet recruiting
Research Site	Curitiba	Paraná	Recruiting
Research Site	Fortaleza	Ceará	Not yet recruiting
Research Site	Natal	Rio Grande do Norte	Not yet recruiting
Research Site	Porto Alegre	Rio Grande do Sul	Not yet recruiting
Research Site	Rio de Janeiro		Not yet recruiting
Research Site	São José dos Campos	São Paulo	Not yet recruiting
Research Site	São Paulo	São Paulo	Not yet recruiting
Research Site	São Paulo	São Paulo	Not yet recruiting

Hungary

Hungary
Facility	City	State or region	Status
Research Site	Budapest		Recruiting
Research Site	Budapest		Not yet recruiting
Research Site	Budapest		Recruiting
Research Site	Budapest	HU	Recruiting
Research Site	Budapest	HU	Recruiting
Research Site	Debrecen	HU	Not yet recruiting
Research Site	Salgótarján		Not yet recruiting
Research Site	Szeged	HU	Not yet recruiting
Research Site	Szolnok		Not yet recruiting
Research Site	Zalaegerszeg		Recruiting

India

India
Facility	City	State or region	Status
Research Site	Bangalore	Karnataka	Not yet recruiting
Research Site	Belagavi	Karnataka	Not yet recruiting
Research Site	Belagavi	Karnataka	Not yet recruiting
Research Site	Calicut	Kerala	Not yet recruiting
Research Site	Chennai	Tamil Nadu	Not yet recruiting
Research Site	Coimbatore	Tamil Nadu	Not yet recruiting
Research Site	Delhi	New Delhi	Not yet recruiting
Research Site	Guntur	Andhra Pradesh	Not yet recruiting
Research Site	Guwahati	Assam	Not yet recruiting
Research Site	Indore	Madhya Pradesh	Not yet recruiting
Research Site	Jaipur	Rajasthan	Not yet recruiting
Research Site	Kochi	Kerala	Not yet recruiting
Research Site	Kolkata	West Bengal	Not yet recruiting
Research Site	Lucknow	Uttar Pradesh	Not yet recruiting
Research Site	Mumbai	Maharashtra	Not yet recruiting
Research Site	Nagpur	Maharashtra	Not yet recruiting
Research Site	Pune	Maharashtra	Not yet recruiting
Research Site	Pune	Maharashtra	Not yet recruiting
Research Site	Thiruvananthapuram	Kerala	Not yet recruiting

Malaysia

Malaysia
Facility	City	State or region	Status
Research Site	Batu Caves	Selangor	Withdrawn
Research Site	Kuala Lumpur	Wilayah Persekutuan Kuala Lump	Not yet recruiting
Research Site	Putrajaya		Not yet recruiting
Research Site	Seremban	Negeri Sembilan	Recruiting
Research Site	Seri Manjung	Perak	Not yet recruiting

Poland

Poland
Facility	City	State or region	Status
Research Site	Bialystok	Podlaskie Voivodeship	Recruiting
Research Site	Częstochowa	Silesian Voivodeship	Not yet recruiting
Research Site	Kielce	Świętokrzyskie Voivodeship	Not yet recruiting
Research Site	Krakow	Malopolska	Not yet recruiting
Research Site	Lodz	Łódź Voivodeship	Recruiting

26 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

August 25, 2026
Site added
5 sites added (76 total)
7176

Registry: ClinicalTrials.gov · NCT########

https://xmedica.io/trials/ctgov/NCT07606066

Categories

Registered in 1 registry

Interested in this study?

How this study is set up

Summary

Conditions

Eligibility

Study population

Eligibility as written in the registry

Eligibility in plain statements

Study design

Sponsor and collaborators

Arms and interventions

Interventions

Outcome measures

Dates

Locations

Brazil

Hungary

India

Malaysia

Poland

Study documents

Changes over time